Common Contracts

3 similar License Agreement contracts by Syros Pharmaceuticals, Inc.

EX-10.14 11 filename11.htm Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and DANA-FARBER CANCER INSTITUTE, INC. and SYROS...
License Agreement • May 5th, 2020 • Massachusetts

This Agreement, effective as of April 1, 2013 (the “EFFECTIVE DATE”), is among the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at Nine Cambridge Center, Cambridge, MA 02142; the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215; and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 480 Arsenal Street, Suite 130, Watertown, MA 02472.

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC....
License Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts

This Agreement, effective as of April 1, 2013 (the “EFFECTIVE DATE”), is among the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at Nine Cambridge Center, Cambridge, MA 02142; the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215; and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 480 Arsenal Street, Suite 130, Watertown, MA 02472.

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC....
License Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts

This Agreement, effective as of April 1, 2013 (the “EFFECTIVE DATE”), is among the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at Nine Cambridge Center, Cambridge, MA 02142; the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215; and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 480 Arsenal Street, Suite 130, Watertown, MA 02472.